Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Elranatamab-bcmm |
| Synonyms | |
| Therapy Description |
Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Elranatamab-bcmm | Elrexfio | PF-06863135|PF06863135|PF 06863135 | CD3 Antibody 99 TNFRSF17 Antibody 20 | Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05014412 | Phase II | Elranatamab-bcmm | MagnetisMM-9: Study of Elranatamab (PF-06863135) Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | GBR | 2 |
| NCT06207799 | Phase II | Elranatamab-bcmm | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | Recruiting | USA | 0 |
| NCT06183489 | Phase II | Elranatamab-bcmm | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM) | Recruiting | NOR | NLD | ITA | GRC | FRA | FIN | 0 |
| NCT05317416 | Phase III | Lenalidomide Elranatamab-bcmm | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) | Recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
| NCT05462639 | Expanded access | Elranatamab-bcmm | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17) | No longer available | USA | CAN | 0 |
| NCT05020236 | Phase III | Elranatamab-bcmm Daratumumab + Dexamethasone + Pomalidomide Daratumumab + Elranatamab-bcmm | MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
| NCT03269136 | Phase I | Elranatamab-bcmm | Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma | Completed | USA | CAN | 0 |
| NCT04649359 | Phase II | Elranatamab-bcmm | Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | Active, not recruiting | USA | POL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
| NCT06138275 | Phase II | Elranatamab-bcmm | Elranatamab in R/R Multiple Myeloma | Recruiting | USA | 0 |
| NCT06057402 | FDA approved | Elranatamab-bcmm | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15) | Recruiting | USA | FRA | CAN | AUS | 1 |
| NCT06282978 | Phase II | Elranatamab-bcmm | Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | Recruiting | ESP | 0 |
| NCT06421675 | Phase II | Elranatamab-bcmm | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE) | Not yet recruiting | CAN | 0 |
| NCT06152575 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide Elranatamab-bcmm | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Recruiting | USA | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | ARG | 1 |
CKB BOOST